Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (September 2022)
27 slides from Prescient Therapeutics's investor presentation, Sep 27, 2022
Slide 1: CellPryme-A Investor Presentation announcement
CellPryme-A Investor Presentation For personal use only MELBOURNE Australia, 27 September 2022 – Prescient Therapeutics (ASX: PTX), a clinical stage oncology company developing personalised therapies to treat cancer, attaches a copy of the investor presentation to launch CellPryme-A, Prescient Thera
Slide 2: About Prescient Therapeutics (continued)
method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time. Prescient is developing OmniCAR programs for next-generation CAR-T therapies for A
Slide 3: Forward-looking statements
statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actua
Slide 4: Unveiling CellPryme-A: Adjuvant for enhancing cell therapies
For personal use only Unveiling Adjuvant for enhancing cell therapies Prescient Therapeutics Limited (ASX: PTX)
Slide 5: Executive Summary
CellPryme-A Executive Summary For personal use only ADJUVANT PLATFORM TO BREAKS DOWN HOSTILE TME ENHANCE CELL THERAPIES • Two-thirds less intratumoral Tregs • Current gen and next gen • Increases CAR-T cell penetration into • Complementary to tumours CellPryme-M & OmniCAR BOOSTS CAR-T IMPROVES TUMOU
Slide 6: What is CellPryme-A?
For personal use only What is CellPryme-A? 3
Slide 7: Introducing CellPryme-A
Introducing CellPryme-A For personal use only CellPryme-A is an adjuvant provided to patients that improves the function of cellular therapies by combating the hostile tumour microenvironment (TME) 4
Slide 8: The CAR-T process
The CAR-T process For personal use only T-Cells are genetically altered to Blood is collected 1 from the patient 2 T-Cells are isolated 3 have cancer-recognising receptors (CARs) CAR-T cells are 4 Millions of CAR-T cells are grown 5 administered to the patient 5
Slide 9: Complementary cell therapy enhancement platforms
Complementary cell therapy enhancement platforms For personal use only MANUFACTURING ADJUVANT ENHANCEMENT THERAPY • Produces longer lasting, • Overcomes hostile TME more “youthful” CAR-T cells • Reduces Tregs • Doubles helper T cells • Increases expansion of CAR-T • Doubles tumour control cells in v
Slide 10: CellPryme Complements OmniCAR
CellPryme Complements OmniCAR For personal use only • Multi-targeting • Redirection • Control & safety • Any target; any cell Adjuvant therapy Process that produces • Reduces Tregs a better cell type • Primes TME for cell • Persistence therapy • Trafficking • Boosts CAR-T cell expansion in vivo Next
Slide 11: Platforms to overcome CAR-T's key challenges
Platforms to overcome CAR-T’s key challenges Challenge For personal use only Safety / Control No control post infusion - Difficulties with targeting, Targeting antigen heterogeneity - Safe Escape Difficulties with mutating antigens - Effective Production efficiency Cost prohibitive & slow -
Slide 12: Overcoming the tumour's hostile microenvironment
For personal use only Overcoming the tumour’s hostile microenvironment 9
Slide 13: The hostile Tumour Microenvironment (TME)
The hostile Tumour Microenvironment (TME) For personal use only • TME is the complex ecosystem surrounding solid tumours • Protects and nurtures the cancer • Grows faster and spreads • Tumours and their TME interact with each other • Acts as a protective “force field” that bluntens the effectiveness
Slide 14: Treg cells are central players in the TME
Treg cells are central players in the TME For personal use only Tregs are immunosuppressive cells in the TME (i.e. suppresses the immune response) • Causes T cell exhaustion • Causes T cell death • Produces cytokines that cause the tumour to go “cold” • Impairs NK cell function Reducing Tregs is key
Slide 15: Compelling data
For personal use only 12 Compelling data
Slide 16: Summary of CellPryme-A effects
Summary of CellPryme-A effects For personal use only Boosts tumour killing by Improved survival conventional CAR-T cells Dramatically increases Reduces problematic CAR-T cell expansion within host Treg cells by 66% • 2x ↑ CAR-T cell expansion • 9x↑ Cytotoxic T cells with CellPryme-M • 6x ↑ Helper T
Slide 17: Significantly decreases problematic Tregs in tumours
CellPryme-A significantly decreases problematic Tregs in tumours For personal use only CellPryme-A significantly reduced intra-tumoural Tregs by two-thirds Conventional Her2 CAR-T cell therapy followed by CellPryme-A adjuvant therapy 14 *p<0.05; Kruskal-Wallis one-way ANOVA
Slide 18: Works via a different mechanism of action to CellPryme-M
CellPryme-A works via a different mechanism of action to CellPryme-M For personal use only CellPryme-A has no significant impact on the T cell phenotype or markers of exhaustion Tim3+ PD-1+ (exhausted CAR-T cells) Tim3- TCF1+ (stem/memory CAR-T cells) % of intratumoural CAR-T cells % of intratumoura
Slide 19: Synergises with CellPryme-M to expand CAR-T cells in vivo
CellPryme-A synergises with CellPryme-M to dramatically expand CAR-T cells in vivo For personal use only ↑9x ↑6x CD8+ Cytotoxic T cells CD4+ T helper cells 16
Slide 20: Significantly increases CAR-T cell penetration into tumours
CellPryme-A significantly increases CAR-T cell penetration into tumours For personal use only ↑3x ↑4x CD4+ T helper cells CD8+ Cytotoxic T cells **p<0.01, ****p<0.0001, Mann-Whitney test Tumours collected from parallel cohort of animals at Day 21 17
Slide 21: Significantly boosts CAR-T efficacy
CellPryme-A significantly boosts CAR-T efficacy For personal use only CAR T cells Experimental end point CellPryme-A (twice a week) Tumour size > 150 mm2 or 28 days unless other humane endpoints are reached 0 7 10 Colon cancer cells are transplanted into the mammary fat pad CellPryme-A + CellPryme
Slide 22: Improves survival
CellPryme-A improves survival For personal use only Survival 100 Probability of Survival (%) • Highly aggressive and resistant cancer model • CAR-T cells did not improve survival in this model • CellPryme-A improved the survival of animals given CAR-T cells by over 20% (5 days) 50 • The combination
Slide 23: Next steps & opportunities
For personal use only Next steps & opportunities 20
Slide 24: Ready for the clinic
CellPryme-A ready for the clinic For personal use only CLINIC-READY THERAPY CAR-T cells • Ready for clinical testing as adjuvant/neoadjuvant therapy • Straightforward to incorporate adjuvant into other CAR-T programs • Robust regulatory package • Clinical grade material available 21
Slide 25: Multiple development opportunities
Multiple development opportunities For personal use only NEW SCALABLE PLATFORM OPPORTUNITY FOR PTX • Prescient to incorporate into internal OmniCAR programs Collaborate & partner with developers of cellular therapies • Boost 3rd party solid tumour CAR-T programs • Straightforward to incorporate Cell
Slide 26: Summary
CellPryme-A Summary For personal use only ADJUVANT PLATFORM TO BREAKS DOWN HOSTILE TME ENHANCE CELL THERAPIES • Two-thirds less intratumoral Tregs • Current gen and next gen • Increases CAR-T cell penetration • Complementary to into tumours CellPryme-M & OmniCAR BOOSTS CAR-T IMPROVES TUMOUR EXPANSIO
Slide 27: Thank you!
For personal use only Thank you! ASX code: PTX www.ptxtherapeutics.com
Prescient Therapeutics — Investor Presentation (September 2022) on 6ix